Hence, the crucial role of Ezh2 in maintaining the functionality of effector T cells and formation of memory precursor T cells emphasizes the potential detrimental effects of targeting Ezh2 in T cells on the outcome of cancer immunotherapy. The gene discussed is EZH2; the disease is cancer.